BioArray Q&A: Roche NimbleGen CEO Gerd Maass on Taking a Tech Company into Personalized Healthcare

Before taking over as CEO of Roche NimbleGen 13 months ago, Gerd Maass spent most of his professional life working in research and development for pharmaceutical and diagnostics companies. Now one of his main goals is steering the firm, which Roche paid $272.5 million to acquire in 2007, towards wider involvement in drug and test development.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.